Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1117-1124

  Foon, Kenneth A ^a   Sen, Goutam ^b   Hutchins, Laura ^b   Kashala, Oscar L ^b   Baral, Rathin ^b   Banerjee, Maitrayee ^b   Chakraborty, Mala ^b   Garrison, Juanita ^b   Reisfeld, Ralph A ^b   Bhattacharya Chatterjee, Malaya ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CYTOKINE; DISIALOGANGLIOSIDE GD2; GANGLIOSIDE GD2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MONOCLONAL ANTIBODY 1A7; QS 21; TUMOR VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNIZATION; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MALE; MELANOMA; MICE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 15644380222     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer, 53: 566-573, 1993.
2. Tsuchida, T., Saxton, R. E., Morton, D. L., and Irie, R. F. Gangliosides of human melanoma. Cancer (Phila.), 63: 1166-1174, 1989.
3. Livingston, P. O., Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, G., Calves, M. J., Helling, F., Ritter, G., Oettgen, H. F., and Old, L. J. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol., 12: 1036-1044, 1994.
4. Livingston, P. O., Ritter, F., Srivastava, P., Padavan, M., Calves, M. J., Oettgen, H. F., and Old, L. J. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res., 49: 7045-7050, 1984.
5. Livingston, P. O., Natoli, E. J., Jr., Calves, M. J., Stocken, E., Oettgen, H. F., and Old, L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA, 84: 2911-2915, 1987.
6. Chapman, P. B., Livingston, P. O., Morrison, M. E., Williams, L., and Houghton, A. N. Immunization of melanoma patients with anti-idiotypic monoclonal antibody BEC2 which mimics GD3 ganglioside: pilot trials using no immunological adjuvant. Vaccine Res., 3: 59-69, 1994.
7. McCaffery, M., Yao, T-J., Williams, L., Livingston, P. O., Houghton, A. N., and Chapman, P. B. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogeneicity when combined with adjuvant. Clin. Cancer Res., 2: 679-686, 1996.
8. Bhattacharya-Chatterjee, M., Pride, M. W., Seon, B. K., and Kohler, H. Idiotype vaccines against human T-cell acute lymphoblastic leukemia (TALL). I. Generations and characterizations of biologically active monoclonal anti-idiotypes. J. Immunol., 5: 562-573, 1987.
9. Bhattacharya-Chatterjee, M., Chatterjee, S. K., Vasile, S., Seon, B. K., and Kohler, H. Idiotype vaccines against T-cell leukemia. II. Generation and characterization of monoclonal idiotype cascade (Ab1, Ab2 and Ab3). J. Immunol., 141: 1398-1403, 1988.
10. Foon, K. A., Oseroff, A. R., Vaickus, L., Greenberg, S. J., Russell, D., Bernstein, Z., Pincus, S., Kohler, H., Seon, B. K., Tahaoglu, E., Beers, T., Chakraborty, M., and Bhattacharya-Chatterjee, M. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin. Cancer Res., 1: 1285-1294, 1995.
11. Foon, K. A., Chakraborty, M., John, W. J., Sherratt, A., Kohler, H., and Bhattacharya-Chatterjee, M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype vaccine. J. Clin. Invest., 96: 334-342, 1995.
12. Foon, K. A., John, W. J., Chakraborty, M., Sherratt, A., Garrison, J., Flett, M., and Bhattacharya-Chatterjee. M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res., 3: 1267-1276, 1997.
13. Sen, G., Chakraborty, M., Foon, K. A., Reisfeld, R. A., and Bhattacharya-Chatterjee, M. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J. Immunother., 21: 75-83, 1998.
14. Sen, G., Chakraborty, M., Foon, K. A., Reisfeld, R. A., and Bhattacharya-Chatterjee, M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin. Cancer Res., 3: 1969-1976, 1997.
15. Mujoo, K., Kipps, T. J., Yang, H. M., Cheresh, D. A., Wargalla, U. C., Sander, D. J., and Reisfeld, R. A. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res., 49: 2857-2861, 1989.
16. Chakraborty, M., Foon, K. A., Kohler, H., and Bhattacharya-Chatterjee, M. Preclinical evaluation in non-human primates of an anti-idiotypic antibody that mimics the carcinoembryonic antigen. J. Immunother., 18: 95-103, 1995.
17. Losman, M. J., Monestier, M., Hansen, H. J., and Goldenberg, D. M. Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope. Int. J. Cancer, 46: 310-314, 1990.
18. Handgretinger, R., Baader, P., Dopfer, R., Klingebiel, T., Reuland, P., Treuner, J., Reisfeld, R. A., and Niethammer, D. A Phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol. Immunother., 35: 199-204, 1992.
19. Mitchell, M. S., Kan-Mitchell, J., Kempf, R. A., Harel, W., Shau, H., and Lind, S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res., 48: 5883-5893, 1988.
20. Mitchell, M. S., Harel, W., Kempf, R. A., Hu, E., Kan-Mitchell, J., Boswell, W.D., Dean, G., and Stevenson, L. Active-specific immunotherapy for melanoma. J. Clin. Oncol., 8: 856-869, 1990.
21. Morton, D. L., Foshag, L. J., Hoon, D. S., Nizze, J. A., Famatiga, E., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., Elashoff, R., et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg., 216: 463-482, 1992.
22. Berd, D., and Mastrangelo, M. J. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest., 6: 337-349, 1988.
23. Ikonopisov, R. L., Lewis, M. G., Hunter-Craig, I. D., Bodenham, D. C., Phillips, T. M., Cooling, C. I., Proctor, J., Fairley, G. H., and Alexander, P. Auto-immunization with irradiated tumor cells in human malignant melanoma. Br. Med. J., 2: 752-754, 1970.
24. Currie, G. A., Lejeune, F., and Hamilton-Fairley, G. Immunization with irradiated tumor cells and specific lymphocyte cytotoxicity in malignant melanoma. Br. Med. J., 2: 305-310, 1971.
25. Laucius, J. F., Bodurtha, A. J., Mastrangelo, M. J., and Bellet, R. E. A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer (Phila.), 40: 2091-2093, 1977.
26. Wallack, M. K., Steplewski, Z., Koprowski, H., Rosato, E., George, J., Hulihan, B., and Johnson, J. A new approach in specific active immunotherapy. Cancer (Phila.), 39: 560-564, 1977.
27. Murray, D. R., Cassel, W., Torbin, A. H., Olkowski, Z. L., and Moore, M. E. Viral oncolysates in the management of malignant melanoma. Cancer (Phila.), 40: 680-686, 1977.
28. Cassel, W. A., Murray, D. R., and Phillips, H. S. A Phase II study of the post surgical management of stage II melanoma with a Newcastle disease virus oncolysate. Cancer (Phila.), 52: 856-860, 1983.
29. Wallack, M. K., Sivanadham, M., Balch, C. M., et al. A Phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer (Phila.), 75: 34-42, 1995.
30. Marchand, M., Weynants, P., Rankin, E., et al. Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3. Int. J. Cancer, 63: 883-885, 1995.
31. Rosenberg, S. A., Anderson, W. F., Blaese, R. M., et al. Immunization of cancer patients using autologous cancer cells modified by the insertion of the gene for interleukin-2. Hum. Gene Ther., 3: 75-90, 1992.
32. Lotze, M. T., and Rubin, J. T. Gene therapy of cancer: a pilot study of IL-4 gene modified fibroblasts with autologous tumor to elicit an immune response. Hum. Gene Ther., 5: 41-55, 1994.
33. Maeurer, M. J., Storkus, W. J., Kirkwood, J. M., and Lotze, M. T. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res., 6: 11-24, 1996.
34. Mastrangelo, M. J., Maguire, H. C., Sato, T., Nathan, F. E., and Berd, D. Active specific immunization in the treatment of patients with melanoma. Semin. Oncol., 23: 773-781, 1996.
35. Quan, W. D. Y., Dean, G. E., Spears, L., Spears, C. P., Groshen, S., Merritt, J. A., and Mitchell, M. S. Active specific immunotherapy of metastatic melanoma with an anti-idiotype vaccine: A Phase I/II trial of I-Mel-2 plus SAF-m. J. Clin. Oncol., 15: 2103-2110, 1997.
36. Mittelman, A., Chen, Z. J., Kageshita, T., et al Active specific immunotherapy in patients with melanoma. A clinical trial with mouse anti-idiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight melanoma-associated antigen monoclonal antibodies. J. Clin. Invest., 86: 2136-2144, 1990.
37. Mittelman, A., Chen, Z. J., Yang, H., Wong, G. Y., and Ferrone, S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA, 89: 466-470, 1992.